Good morning :)
Place Order
Add to Watchlist

Mankind Pharma Ltd

MANKIND

Mankind Pharma Ltd

MANKIND
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,04,078 cr, stock is ranked 85
Moderate RiskStock is 2.35x as volatile as Nifty
2,597.650.00% (+0.00)
2,597.650.00% (+0.00)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,04,078 cr, stock is ranked 85
Moderate RiskStock is 2.35x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹1,04,078 cr, stock is ranked 85
Moderate RiskStock is 2.35x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
49.2110.87
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.886.300.52%

Forecast & Ratings

Detailed Forecast 
80%
Analysts have suggested that investors can buy this stock

from 15 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

Investor Presentation

View older 

Nov 5, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue5,987.196,397.067,992.048,890.4210,630.8411,403.77
Raw Materialssubtract1,888.532,028.002,871.322,622.903,263.378,288.58
Power & Fuel Costsubtract79.9682.53103.13108.96129.30
Employee Costsubtract1,335.531,415.781,620.591,918.472,274.73
Selling & Administrative Expensessubtract885.851,086.441,410.011,616.921,880.42
Operating & Other expensessubtract237.29-47.44-214.04580.25250.37
Depreciation/Amortizationsubtract99.06118.97166.62325.92398.25427.78
Interest & Other Itemssubtract23.2421.1659.8045.7635.0536.58
Taxes & Other Itemssubtract407.31426.19541.12389.39486.46535.87
EPS25.7231.5935.7832.0047.7552.80
DPS0.007.600.000.000.000.00
Payout ratio0.000.240.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 2PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 5PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Mankind Pharma Ltd54.4110.87
Sun Pharmaceutical Industries Ltd44.306.320.76%
Cipla Ltd29.394.520.87%
Torrent Pharmaceuticals Ltd63.3915.310.90%

Price Comparison

Compare MANKIND with any stock or ETF
Compare MANKIND with any stock or ETF
MANKIND
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.87%6.99%2.91%12.37%2.86%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep4.18%4.18%6.74%9.87%11.58%12.37%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Mankind Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
SBI Blue Chip Fund - Growth - Direct Plan

Growth
0.7380%1.48%0.37%23/57 (+11)
Axis ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.3102%0.86%0.24%32/98 (-1)
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI CONTRA FUND DIRECT PL GROWTH

Growth
0.2793%0.70%0.13%82/112 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Mankind Pharma Ltd

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Spotlight
Mankind Pharma Ltd slips for fifth straight session

Mankind Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2537.6, down 3.22% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Mankind Pharma Ltd has lost around 8.04% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 2.1 lakh shares today, compared to the daily average of 3.25 lakh shares in last one month.The PE of the stock is 52.54 based on TTM earnings ending September 24.Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
Mankind Pharma receives reaffirmation in credit rating from CRISIL

Mankind Pharma has received reaffirmation in credit ratings from CRISIL as under: Commercial paper (Rs 5,000 crore) - CRISIL A1+ Non convertible debentures (Rs 4,600 crore) - CRISIL AA+/ Stable Non convertible debentures (Rs 400 crore) - CRISIL AA+/ Stable Total bank loan facilities rated (Rs 1,250 crore) - CRISIL AA+/ Stable Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Mankind Pharma consolidated net profit rises 30.43% in the September 2024 quarter

Net profit of Mankind Pharma rose 30.43% to Rs 653.47 crore in the quarter ended September 2024 as against Rs 501.03 crore during the previous quarter ended September 2023. Sales rose 13.60% to Rs 3076.51 crore in the quarter ended September 2024 as against Rs 2708.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3076.512708.10 14 OPM %27.6325.21 - PBDT954.94737.48 29 PBT849.32640.99 33 NP653.47501.03 30 Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Mankind Pharma Ltd spurts 0.01%, up for fifth straight session

Mankind Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 2681.1, up 0.01% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 1.72% on the day, quoting at 23886.05. The Sensex is at 78452.42, down 1.6%. Mankind Pharma Ltd has gained around 4.66% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 1.9% in last one month and is currently quoting at 22807.15, down 1.17% on the day. The volume in the stock stood at 2.14 lakh shares today, compared to the daily average of 2.7 lakh shares in last one month.The PE of the stock is 57.5 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Mankind Pharma Ltd spurts 3.89%

Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2729.95, up 3.89% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.6% on the day, quoting at 24194.3. The Sensex is at 79405.35, down 0.67%. Mankind Pharma Ltd has risen around 5.86% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has risen around 2.54% in last one month and is currently quoting at 22374.95, up 1.48% on the day. The volume in the stock stood at 1.53 lakh shares today, compared to the daily average of 2.98 lakh shares in last one month.The PE of the stock is 56.17 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Mankind Pharma to convene board meeting

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Mankind Pharma receives ratings action from ICRA

Mankind Pharma has received reaffirmation in credit rating for non-convertible debentures (Rs 4,600 crore) at ICRA AA+; Stable. The company has been assigned the rating ICRA A1+ and ICRA AA+; Stable for commercial papers (Rs 5,000 crore), non-convertible debentures (Rs 400 crore) and bank facilities (Rs 1,250 crore). Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Mankind Pharma Ltd soars 3.76%

Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2631.1, up 3.76% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.3% on the day, quoting at 25867.5. The Sensex is at 84684.03, up 0.17%. Mankind Pharma Ltd has risen around 11.82% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has risen around 2.38% in last one month and is currently quoting at 23005.25, up 0.37% on the day. The volume in the stock stood at 6.1 lakh shares today, compared to the daily average of 6.37 lakh shares in last one month.The PE of the stock is 54.44 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Mankind Pharma hits record high after board OKs to raise Rs 10,000 cr

The company will raise funds by way of issuance of non-convertible debentures (NCDs) and Commercial Papers (CPs) on private placement basis for an amount aggregating upto Rs 10,000 crore. The board has also constituted and authorized the Fund Raising Committee to take all necessary actions including finalization of the terms of issuance, allotment of NCDs and CPs and other related matters. Meanwhile, the company's board also approved corporate guarantees for its subsidiaries, Mankind Agritech Private, Appian Properties, Copmed Pharmaceuticals Private and Lifestar Pharma LLC. Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. The pharmaceutical company reported 10.19% increase in consolidated net profit to Rs 536.49 crore in Q1 FY25 as against Rs 486.87 crore posted in Q1 FY24.Revenue from operations stood at Rs 2,893.42 crore in Q1 FY25, up 12.20% as against with Rs 2,578.62 crore in Q1 FY24. The scrip hit all-time high at Rs 2,645 in intraday today.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Mankind Pharma board OKs to raise Rs 10,000 cr

The company will raise funds by way of issuance of non-convertible debentures (NCDs) and Commercial Papers (CPs) on private placement basis for an amount aggregating upto Rs 10,000 crore. The board has also constituted and authorized the Fund Raising Committee to take all necessary actions including finalization of the terms of issuance, allotment of NCDs and CPs and other related matters. Meanwhile, the company's board also approved corporate guarantees for its subsidiaries, Mankind Agritech Private, Appian Properties, Copmed Pharmaceuticals Private and Lifestar Pharma LLC. Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. The pharmaceutical company reported 10.19% increase in consolidated net profit to Rs 536.49 crore in Q1 FY25 as against Rs 486.87 crore posted in Q1 FY24.Revenue from operations stood at Rs 2,893.42 crore in Q1 FY25, up 12.20% as against with Rs 2,578.62 crore in Q1 FY24. The counter rallied 4.78% to ends at Rs 2,547.15 on Friday, 20 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live